Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996182 | 0.82 | SLC6A3 (0.55) | SLC6A3PDE10A | |
| SCHEMBL1758612 | 0.81 | SLC6A3 (0.72) | SLC6A3PDE10A | |
| SCHEMBL24950777 | 0.80 | BRAF (0.57) | BRAFMEN1KMT2ASLC6A3MAPK3 | |
| SCHEMBL1758497 | 0.80 | PDE10A (0.51) | SLC6A3PDE10A | |
| SCHEMBL1758722 | 0.79 | PDE10A (0.71) | SLC6A3PDE10A | |
| SCHEMBL187150 | 0.79 | PDE10A (0.70) | PDE10A | |
| SCHEMBL17088198 | 0.78 | BRAF (0.60) | BRAFMEN1KMT2ASLC6A3MAPK3 | |
| SCHEMBL29280467 | 0.77 | BRAF (0.44) | BRAFMEN1KMT2ASLC6A3MAPK3 | |
| SCHEMBL5256066 | 0.77 | MAPK14 (0.62) | BRAFMEN1KMT2ASLC6A3MAPK13 | |
| SCHEMBL24951243 | 0.76 | BRAF (0.43) | BRAFMEN1KMT2ASLC6A3MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2493513-B1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051324-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051324-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | PDE9A, PDE10A, PDE7A | BRAF 4475/4885MEN1 1200/4885KMT2A 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.